EUCTR2011-000124-15-DE进行中（未招募）1 期
An Open-Label, Multi-Center Phase I/IIa Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphomas
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Have a histological confirmed aggressive non-Hodgkin’s lymphoma that is not amenable to standard therapy with curative intent or that has progressed or recurred after prior standard therapy.
- •(2) Have received at least 1 line of standard chemotherapy
- •(3) Have at least one measurable lesion by computerized tomography (CT) or other techniques, that has not been previously irradiated, or has grown since the previous irradiation.
- •(4) Male or female patient at least 18 years old.
- •(5) ECOG performance status 0, 1, or 2. See Appendix B.
- •(6) Life expectancy of at least 12 weeks.
- •(7) Patient has adequate organ and immune system function as indicated by the laboratory values in the protocol
- •(8) Any chemotherapy, major surgery, or irradiation must have been completed at least 4 weeks prior to starting treatment with study drug (a minimum 12 weeks or four half-lives whichever is greater for monoclonal antibodies; 12 weeks for vaccines; and 8 weeks for radioimmunotherapy). Additionally, patients must have recovered from clinically significant toxicities incurred as a result of previous therapy except nail dystrophy, alopecia, grade 1 peripheral neuropathy, or local radiation therapy induced
- •effects (impotence or incontinence)
- •(9) Be able to comply with study procedures and follow-up examinations.
- •(10) Not pregnant or lactating. Male and female patients who are fertile must agree to use an effective means of birth control to avoid pregnancy. Acceptable birth control method requires the use of a double-barrier method (meaning the man to use a condom plus additional methods, like oral contraceptives, intra-uterine device, spermicidal foam).
- •(11) Signed informed consent.
- •(12) Patients on immune-suppressive agents such as corticosteroids may be enrolled, however, (s)/he must be on stable dose for at least 4 weeks prior start of study therapy and are planned to continue with the same dose while in the trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 23
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •(1) Patients with known or symptomatic or progressive meningeal infiltration.
- •(2) Received previous treatment with Tasidotin HCl or known hypersensitivity to Tasidotin HCl or its analogues.
- •(3) Prior autologous or allogenic marrow or stem cell transplant within 6 months of study entry.
- •(4) Blood transfusions within 4 weeks of study entry.
- •(5) Used any investigational agents during the 30 days prior to the first dose.
- •(6) Has any clinical indication that may affect gastrointestinal (GI) absorption (e.g., diarrhea, ulcers, GI surgery, or other GI abnormalities).
- •(7) History of other malignancy that could affect compliance with the protocol or interpretation of results
- •(8) Has psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.
- •(9) Has uncontrolled congestive heart failure (CHF) or angina, including patients with a history of myocardial infarction within 2 months of enrollment, or patients with cardiac functional capacity Class III or IV as defined by the New York Heart Association Classification. See Appendix D.
- •(10) Has a systemic fungal, bacterial, viral, or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement) despite appropriate antibiotics or other treatment.
- •(11) Known human immunodeficiency virus (HIV) positivity.
- •(12) Has any other severe concurrent disease, or have a history of serious organ
- •dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo chemotherapy.
- •(13) Patient is a dependant of the investigator or sponsor (e.g., family, relatives, employee…)
研究者
相似试验
进行中（未招募）
1 期
Gene Therapy Trial for LCA2 OPTIRPE65eber Congenital Amaurosis (LCA) caused by mutations in RPE65MedDRA version: 20.0Level: PTClassification code 10070667Term: Leber's congenital amaurosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003418-25-GBMeiraGTx UK II Ltd27
进行中（未招募）
1 期
Gene Therapy Trial for People with Achromatopsia (unable to see colours) due to a gene defectAchromatopsia caused by mutations in the CNGB3 geneMedDRA version: 20.0 Level: LLT Classification code 10000454 Term: Achromatopsia System Organ Class: 100000004850EUCTR2016-002290-35-GBMeiraGTx UK II Limited27
进行中（未招募）
1 期
Gene Therapy Trial for patients with Achromatopsia due to a gene defect (CNGA3)EUCTR2018-003431-29-GBMeiraGTx UK II Limited36
进行中（未招募）
1 期
Gene Therapy Trial for People with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X.X-Linked Retinitis Pigmentosa caused by mutations in the RPGR geneMedDRA version: 20.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-003967-21-GBMeiraGTx UK II Limited71
进行中（未招募）
1 期
Study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in BRAF mutant metastatic colorectal cancerBRAF mutant metastatic colorectal cancerMedDRA version: 18.1 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002138-35-BEArray BioPharma Inc.162